Breaking News, Collaborations & Alliances

Ribo, Boehringer Ingelheim Partner on Liver Disease Treatment

Will leverage Ribo's RIBO-GalSTAR platform for the development of RNAi therapeutics targeting disease-causing genes.

Suzhou Ribo Life Science Co., Ltd. and Ribocure AB entered into a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). The partnership brings together Ribo’s discovery and clinical development of small interfering RNA (siRNA) therapeutics with Boehringer’s  cardiovascular, renal, and metabolic diseases (CRM) expertise. Ribo will receive an upfront payment and success-based milestones f...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters